Glucagon Binding and Adenylate Cyclase Activity in Liver Membranes from Untreated and Insulin-Treated Diabetic Rats

Vijay Soman and Philip Felig, The Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut 06510

Abstract To investigate the role of hepatic glucagon receptors in the hypersensitivity to glucagon observed in insulin-deprived diabetics, liver plasma membranes were prepared from control rats and from streptozotocin-induced diabetic rats some of whom were treated with high-dose and low-dose insulin. The untreated diabetic animals exhibited hyperglycemia, weight loss, hypoinsulinemia, and hyperglucagonemia. High-dose insulin treatment (2 U Protamine-zinc-insulin/100 g per day) resulted in normoglycemia, normal weight gain, mild hyperinsulinemia, and return of glucagon levels toward base line. The low-dose (1 U protamine-zinc-insulin/100 g per day) insulin-treated diabetic group demonstrated chemical changes intermediate between the untreated and the high-dose insulin-treated animals.

In liver plasma membranes from the untreated diabetic rats, specific binding of $^{125}$I-glucagon was increased by 95%. Analysis of binding data suggested that the changes in glucagon binding were a consequence of alterations in binding capacity rather than changes in binding affinity. Furthermore, in the untreated diabetic rats, both basal and glucagon (2 μM)-stimulated adenylate cyclase activity were twofold higher than in controls. In the high-dose insulin-treated diabetic rats, glucagon binding and basal and glucagon-stimulated adenylate cyclase activity were normalized to control values, whereas low-dose insulin treatment resulted in changes intermediate between control and untreated diabetic rats. In contrast to glucagon-stimulated adenylate cyclase activity, fluoride-stimulated adenylate cyclase activity was similar in all groups of rats. Liver plasma membranes from untreated and insulin-treated diabetic animals degraded $^{125}$I-glucagon to the same extent as control rats.

The specific binding of $^{125}$I-insulin in the untreated diabetic animals was 40% higher than in control rats. In low-dose insulin-treated diabetic rats, insulin binding was not significantly different from that of control rats, whereas in the high-dose insulin-treated group in whom plasma insulin was 70% above control levels, insulin binding was 30% lower than in control rats.

These findings suggest that alterations in glucagon receptors may contribute to the augmented glycemic and ketonemic response to glucagon observed in insulin-deprived diabetics.

Introduction

Diabetes has been described as a bihormonal disease due not only to insulin deficiency but also to glucagon excess (1). Recent studies from our laboratory indicate that physiologic hyperglucagonemia does not of itself lead to deterioration of diabetic control when insulin is available (2). However, when juvenile-onset diabetics are deprived of insulin, an exaggerated hyperglycemic response to glucagon is observed (2). Furthermore, more recent studies of Barnes et al. (3) indicate that although glucagon is not essential for the fasting hyperglycemia and hyperketonemia of diabetes, in situations of insulin deficiency endogenous hyperglucagonemia does exacerbate hyperglycemia and ketonemia. Although these studies underscore the primary role of insulin deficiency in the hypersensitivity to glucagon in diabetes (2, 3), the cellular mechanism whereby insulin availability modulates the glycemic and ketonemic response to glucagon remains unknown. Changes in glucagon receptors have recently been implicated in some of the conditions characterized by altered tissue sensitivity to glucagon. For example, decreased hepatic sensitivity to glucagon in the fetus has been ascribed to a decrease in glucagon...
binding and adenylyl cyclase activity in fetal liver plasma membranes (4, 5). Furthermore, in recent studies employing a partially nephrectomized uremic rat model, we reported that alterations in hepatic glucagon and insulin receptors may account for the glucagon hypersensitivity and insulin resistance observed in the glucose intolerance of uremic humans (6). The present study was consequently undertaken to determine whether glucagon hypersensitivity in insulin-deprived diabetics might be mediated by alterations in hepatic glucagon receptors. In this investigation, we have examined the glucagon binding and the adenylyl cyclase activity in liver membranes from diabetic rats with and without insulin treatment.

METHODS

Experimental animals. Adult Sprague-Dawley rats weighing 200–300 g were used in all experiments. The animals were maintained on standard Purina Chow (Ralston Purina Co., St. Louis, Mo.) and were given free access to water. Diabetes was induced by a single injection of streptozotocin (65 mg/kg of body wt) into the dorsal tail vein. Streptozotocin was dissolved immediately before use in a citric acid buffer adjusted to pH 4.5 and 0.2 ml of solution was injected. Control rats received the diluent only. The streptozotocin-treated rats developed glycosuria, polydipsia, and hyperglycemia within 48 h after injection. On day 3 after streptozotocin injection, plasma glucose was measured, and only those rats with plasma glucose of 300 mg/100 ml or higher were included in the study. Diabetic rats were divided into three groups: (a) untreated diabetics; (b) high-dose insulin treatment group; and (c) low-dose insulin treatment group. The high-dose and low-dose insulin treatment groups received, respectively, 2 U and 1 U of Protamine-zinc-insulin (PZI) per 100 g body wt at 9 a.m. daily for 7 days beginning 3 days after the administration of streptozotocin. The dose of insulin was chosen on the basis of a pilot study which involved measurement of plasma glucose, urine sugar, and body weight twice daily on various Protamine-zinc-insulin dose regimens. The insulin-treated rats were sacrificed 20–24 h after their last insulin dose, 7 days after institution of insulin treatment (10 days after streptozotocin). The untreated animals were sacrificed 10 days after streptozotocin administration. Livers were quickly removed and blood was obtained by aortic puncture for measurement of plasma glucose, insulin, and glucagon levels.

Preparation of liver plasma membranes. After removal, livers were quickly minced in 0.25 M ice-cold sucrose and homogenized in 0.001 M NaHCO₃ solution in a Dounce homogenizer (Kontes Co., Vineland, N. J.) at 4°C. Partially purified plasma membranes were prepared by the method of Neville (7) as modified by Pohl et al. (8). The preparation sequence was rigidly followed for membranes of all groups of rats. The specific activity of the plasma membrane marker enzyme, 5′-nucleotidase, was measured by the method of Avruch and Wallach (9), and the microsomal marker enzyme, glucose-6-phosphatase, was measured by the method of Swanson (10). Membrane protein was estimated by the method of Lowry et al. (11). Membrane preparations were stored in small aliquots at −70°C for 1 mo without any significant decrease in adenylyl cyclase activity or hormone binding.

Iodination of insulin and glucagon. ¹²⁵I-Insulin was prepared by the chloramine-T method at sp act of 150–200 μCi/μg according to the method of Freychet et al. (12). This method has been shown to yield a biologically active moniodoinsulin preparation. Glucagon was iodinated by a modification (13) of the Hunter and Greenwood method (14) as described previously (6). Biological activity of moniodinated glucagon prepared by this method has been shown to be similar to that of unlabeled hormone (13). The specific activity of ¹²⁵I-glucagon was 150–200 μCi/μg. Trichloroacetic acid precipitability of both iodinated hormones was >95%. Iodinated hormones were stored at −20°C and used within 2 wk.

Glucagon binding assay. The binding of ¹²⁵I-glucagon to hepatic plasma membranes was carried out according to the method of Rodbell (15) as described earlier (6). Briefly, liver membranes (40–50 μg protein) were incubated for 20 min at 30°C in a medium containing 20 mM Tris-HCl, 1 mM EDTA, 2% bovine serum albumin, pH 7.6, 0.2 nM of ¹²⁵I-glucagon, and varying concentrations of unlabeled glucagon. The incubation volume was 250 μl. At the end of the incubation period, bound ¹²⁵I-glucagon was separated by centrifugation in a Beckman Microfuge B (Beckman Instruments, Inc., Spinco Div., Palo Alto, Calif.) at 4°C as described previously (6). The specific binding of ¹²⁵I-glucagon was calculated by subtracting nonspecific binding (¹²⁵I-glucagon bound in the presence of 1,000 ng/ml glucagon) from the total ¹²⁵I-glucagon binding (in the absence of unlabeled glucagon).

Measurements of adenylyl cyclase activity. Adenylyl cyclase activity in liver membranes was measured according to the procedure of Steiner et al. (16) as described previously (6). The incubation medium contained in 100 μl, 20 mM Tris-HCl, pH 7.6, 5 mM MgCl₂, 1 mM EDTA, 10 mM theophylline, 0.15% bovine serum albumin, 4 mM ATP, creatine kinase (1 mg/ml), 25 mM phosphocreatine, and 50–60 μg of membrane protein. Creatine kinase and phosphocreatine solutions were prepared fresh for each experiment. Stimulation of adenylyl cyclase activity was measured by the addition of 2 μM glucagon, 10 μM epinephrine, and 15 mM sodium fluoride. Incubation was carried out for 10 min at 30°C, and the reaction was stopped by boiling for 3 min. After centrifugation at 3,000 rpm for 15 min at 4°C, aliquots of supernatant were assayed for 3′, 5′-cyclic AMP by radioimmunoassay (16). Specificity of the assay was confirmed by demonstrating that cyclic AMP could no longer be measured after treatment of membranes with purified bovine phosphodiesterase. Recovery of added cyclic AMP in the assay system was at least 90%.

Glucagon degradation by liver plasma membranes. Liver plasma membranes from control and diabetic rats were incubated at a concentration of 0.2 mg membrane protein/ml with 0.2 nM ¹²⁵I-glucagon under the glucagon binding conditions described earlier. At the end of the incubation period, the incubation mixture was transferred to a microfuge tube and centrifuged for 2 min at 10,000 g in a Beckman microfuge model B. The supernate was divided into aliquots and the degradation of the labeled hormone in the supernate was measured as described earlier (6) using three different methods: (a) precipitation by trichloroacetic acid, (b) binding to fresh liver membranes, and (c) adenylyl cyclase activation. In each experiment, appropriate control tubes were prepared which were identical to experimental tubes in all respects except that liver membranes were omitted. In all experiments there was <5% degradation of labeled hormone in control tubes. Percentage of intact hormone in methods 2 and 3 was calculated by using standard curves for glucagon binding and adenylyl cyclase activity. Results were calculated as follows:

\[
\text{percent degradation of labeled hormone by liver membrane} = \left(1 - \frac{\text{% intact hormone in experimental tube}}{\text{% intact hormone in control tube}}\right) \times 100.
\]
Insulin binding assay. $^{125}$I-Insulin binding studies were done by the method of Kahn et al. (17) as described earlier (6). The specific binding of $^{125}$I-insulin was calculated by subtracting nonspecific binding ($^{125}$I-insulin bound in the presence of 1,000 ng/ml of unlabeled insulin) from the total $^{125}$I-insulin binding ($^{125}$I-insulin bound in the absence of unlabeled insulin). Insulin binding data were analyzed by Scatchard analysis (18) and the "average affinity profile" method (19).

Reagents. Crystalline porcine glucagon and crystalline porcine insulin were a gift from Eli Lilly and Company (Indianapolis, Ind.). Carrier-free $^{125}$I-Na was obtained from New England Nuclear (Boston, Mass.). Cellulose powder was obtained from Arthur H. Thomas Co. (Philadelphia, Pa.). Reagents for cyclic AMP radioimmunoassay were purchased from Schwarz/Mann Div., Becton, Dickinson & Co. (Orangeburg, N. Y.). All other reagents were analytical grade.

Blood and plasma measurements. Plasma immunoreactive insulin and immunoreactive glucagon (using Unger antibody 30K) were determined as described previously (20). Glucose was measured by the glucose oxidase technique (21).

RESULTS

Body weight, plasma glucose, insulin, and glucagon (Table I). During the course of the study, the untreated diabetic rats lost 18% of their body weight. In contrast, diabetic animals treated with the low-dose insulin regimen maintained their body weight, whereas those treated with high-dose insulin gained approximately the same weight as the control rats. Plasma glucose levels in the untreated and the low-dose insulin-treated diabetic animals were, respectively, four to fivefold and twofold greater than in the control rats, whereas high-dose insulin treatment resulted in normalization of the plasma glucose. As expected, the plasma insulin concentration in untreated diabetic animals was reduced by 67% as compared with controls. In the diabetic animals treated with the low-dose insulin regimen, plasma insulin levels rose 75% above the concentration in the untreated group, but were still 40% below the normal controls. In the diabetic rats treated with the high-dose insulin regimen, plasma insulin levels were somewhat higher than in control animals. As expected (22), plasma glucagon levels were threefold higher in untreated diabetic animals as compared with controls. The hyperglucagonemia in the diabetic animals was reversed by insulin treatment in a dose-dependent manner (Table I). In the low-dose insulin group, plasma glucagon was reduced by 45% as compared to the untreated diabetics, whereas in the high-dose insulin group plasma glucagon fell by 60%.

Hepatic plasma membrane purification. Table II summarizes the data on the membrane protein yield and the marker enzyme activity in liver membranes from control and diabetic rats. It is evident that the yield of membrane protein was identical in all four groups of animals. The untreated diabetic rats had significantly lower 5'-nucleotidase activity than control rats ($P < 0.01$). This finding is in keeping with that reported by other workers (23, 24). Furthermore, both in the low-dose and in the high-dose insulin-treated groups 5'-nucleotidase activity increased to levels that were not significantly different from that of control rats. More importantly, as shown in Table II, purification of 5'-nucleotidase was identical in all four groups. With respect to glucose-6-phosphatase activity, plasma membranes from the untreated diabetic animals had significantly higher glucose-6-phosphatase activity compared with controls. Other workers have reported similar findings (23, 24). It is of note that in all four groups of animals the specific activity of the plasma membrane marker enzyme, 5'-nucleotidase was increased 18- to 20-fold in partially purified liver membranes over that in the homogenate, whereas the specific activity of the microsomal enzyme, glucose-6-phosphatase in the liver plasma membrane preparation was less than that of the whole homogenate.

Effect of diabetes on glucagon binding and adenylate cyclase activity (Table III). Specific binding of $^{125}$I-glucagon was studied in the control rats and in the untreated and insulin-treated diabetic rats. Glucagon binding was found to be linear over a range of membrane protein concentrations of 0.025–1.4 mg/ml. In the control rats the specific binding of $^{125}$I-glucagon

| TABLE I |
| Influence of Diabetes on Body Weight and Plasma Glucose, Insulin, and Glucagon* |
|---|---|---|---|
| | Diabetic rats | Insulin treatment |
| | Control rats | Untreated | Low dose | High dose |
| | (n = 16) | (n = 18) | (n = 8) | (n = 12) |
| Body weight, g | | | | |
| Basal | $256 \pm 15$ | $267 \pm 18$ | $262 \pm 16$ | $258 \pm 12$ |
| At the time of sacrifice | $291 \pm 16$ | $220 \pm 12$ | $256 \pm 13$ | $299 \pm 16$ |
| Plasma glucose, mg/100 ml | | | | |
| 3 days after streptozotocin | — | $485 \pm 30$ | $502 \pm 24$ | $510 \pm 22$ |
| At the time of sacrifice | $102 \pm 8$ | $476 \pm 21$ | $198 \pm 18$ | $106 \pm 12$ |
| Plasma insulin, \(\mu U/ml\) | | | | |
| At the time of sacrifice | $24 \pm 4$ | $8 \pm 1$ | $14 \pm 2$ | $41 \pm 5$ |
| Plasma glucagon, pg/ml | | | | |
| At the time of sacrifice | $62 \pm 6$ | $196 \pm 10$ | $112 \pm 8$ | $84 \pm 5$ |

* Data are presented as mean±SE.
in this study was in the same range as that reported by Rodbell et al. (15). Glucagon binding in the untreated diabetic rats was 95% higher than in control rats \((P < 0.001, \text{Table III})\). In the low-dose insulin-treated diabetic animals, glucagon binding fell by 30% as compared to the untreated diabetic rats \((P < 0.01)\), but was still 35% higher than in control animals \((P < 0.01)\). In the high-dose insulin-treated diabetic group, the glucagon binding fell to values not significantly different from control rats (Table III). In contrast to the specific binding of 

\[ ^{23} \text{H} \text{glucagon} \] 

the non-specific binding of labeled glucagon was identical in the control (1.5%), in the untreated diabetics (1.6%), and in the insulin-treated diabetic rats (low dose 1.4%, high dose 1.8%).

The finding of increased glucagon binding in diabetic rats led us to investigate the adenylate cyclase activity in liver membranes from these rats because activation of adenylate cyclase is the next well-recognized step in the interaction between glucagon and its target organs. Both basal and stimulated adenylate cyclase activity were measured in the liver plasma membranes from each group of rats. As shown in Table III, in the untreated diabetic animals basal adenylate cyclase was 90% higher than in control rats \((P < 0.001)\). In the low-dose insulin-treated rats, basal adenylate cyclase

### Table II

**Protein Yield and Marker Enzyme Activities in Liver Membranes from Control and Diabetic Rats**

<table>
<thead>
<tr>
<th>Enzyme Activity</th>
<th>Control rats ((n = 16))</th>
<th>Untreated ((n = 18))</th>
<th>Low dose ((n = 8))</th>
<th>High dose ((n = 12))</th>
</tr>
</thead>
<tbody>
<tr>
<td>Protein yield, mg/g wet liver weight</td>
<td>1.70±0.15</td>
<td>1.62±0.12</td>
<td>1.58±0.16</td>
<td>1.75±0.20</td>
</tr>
<tr>
<td>5'-Nucleotidase activity†</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Homogenate</td>
<td>3.1±0.16</td>
<td>2.0±0.18†</td>
<td>2.9±0.2</td>
<td>2.9±0.8</td>
</tr>
<tr>
<td>Plasma membranes</td>
<td>56.4±3.0</td>
<td>38.0±4.0†</td>
<td>54.0±4.8</td>
<td>58.8±4.5</td>
</tr>
<tr>
<td>Purification of 5'-nucleotidase§</td>
<td>18.2</td>
<td>19.0</td>
<td>18.6</td>
<td>20.8</td>
</tr>
<tr>
<td>Glucose-6-phosphatase activity†</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Homogenate</td>
<td>3.4±0.6</td>
<td>5.2±0.8†</td>
<td>4.7±0.7</td>
<td>4.4±0.6</td>
</tr>
<tr>
<td>Plasma membranes</td>
<td>2.6±0.3</td>
<td>4.1±0.5†</td>
<td>3.4±0.3</td>
<td>3.8±0.3</td>
</tr>
<tr>
<td>Purification of glucose-6-phosphatase§</td>
<td>0.76</td>
<td>0.78</td>
<td>0.72</td>
<td>0.86</td>
</tr>
</tbody>
</table>

* Data are presented as mean±SE.
† Specific activities are expressed as micromoles of substrate metabolized per milligram protein per hour.
§ Calculated as specific activity of the enzyme of plasma membrane/specific activity of the enzyme of whole homogenate.

### Table III

**Influence of Diabetes on Glucagon Binding and Adenylate Cyclase Activity in Liver Membranes**

<table>
<thead>
<tr>
<th>Enzyme Activity</th>
<th>Control rats ((n = 16))</th>
<th>Untreated ((n = 18))</th>
<th>Low dose ((n = 8))</th>
<th>High dose ((n = 12))</th>
</tr>
</thead>
</table>
| Specific binding of 

\[ ^{23} \text{H} \text{glucagon} \] 

<table>
<thead>
<tr>
<th>Adenylate cyclase activity†</th>
<th>Basal</th>
<th>Glucagon (2 µM)</th>
<th>Epinephrine (10 µM)</th>
<th>NaF (15 mM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>nmol of 3'-5' cyclic AMP/ mg protein/10 min</td>
<td>0.45±0.07</td>
<td>4.60±0.18</td>
<td>0.90±0.12</td>
<td>3.05±0.28</td>
</tr>
<tr>
<td></td>
<td>24.5±1.6</td>
<td>9.20±0.96</td>
<td>1.54±0.22</td>
<td>3.75±0.22</td>
</tr>
<tr>
<td></td>
<td>17.1±1.9</td>
<td>6.74±0.52</td>
<td>1.06±0.09</td>
<td>3.42±0.32</td>
</tr>
<tr>
<td></td>
<td>11.8±1.0</td>
<td>4.92±0.30</td>
<td>0.98±0.06</td>
<td>3.16±0.31</td>
</tr>
</tbody>
</table>

* Data are presented as mean±SE for 0.2 mg membrane protein/ml of incubation medium.
† Data are presented as mean±SE.

Glucagon Binding and Adenylate Cyclase Activity in Diabetes 555
activity was 25% lower than in the untreated diabetic group (P < 0.05) but was still 38% higher than in the control rats (P < 0.05). In the high-dose insulin-treated diabetic rats, basal adenylate cyclase was the same as that in control animals. Similar changes were observed in glucagon-stimulated adenylate cyclase activity. In the untreated diabetic animals, glucagon-stimulated adenylate cyclase activity was 100% higher than in control animals (P < 0.001). The high-dose insulin-treated diabetic rats showed values comparable to controls, whereas in the low-dose group the response was intermediate between the values in control rats and untreated diabetic rats. The absolute increment above basal in adenylate cyclase activity induced by glucagon was 4.15±0.24 in control rats as compared with 8.36±0.90 in the untreated diabetic rats (P < 0.001) and 6.12±0.62 in the low-dose insulin-treated group (P < 0.05 vs. controls or untreated diabetes) and 4.51±0.30 in the high-dose insulin-treated diabetic animals (P > 0.5 vs. controls). When 10 μM of epinephrine was added to liver membranes from control rats, adenylate cyclase activity was stimulated to a significantly lesser extent than by the addition of 2 μM of glucagon. This observation is similar to that reported by other workers (25). As in the case of glucagon, epinephrine–stimulated adenylate cyclase was significantly higher in untreated diabetic rats than in control animals (P < 0.01). However, epinephrine-stimulated adenylate cyclase activity was fully normalized by low-dose as well as high-dose insulin treatment of diabetic animals. In contrast to the effects of glucagon and epinephrine, the increment in adenylate cyclase activity induced by sodium fluoride in controls (2.60±0.21) was not significantly different from that observed in the untreated diabetic rats (2.91±0.22) or the insulin-treated diabetic animals (low dose 2.75±0.30, high dose 2.80±0.28).

In Fig. 1, the effects of varying concentrations of glucagon on the binding of 125I-glucagon and on the activation of adenylate cyclase are compared. In the control as well as in the diabetic rats (Fig. 1), saturation of binding sites or activation of adenylate cyclase occurred in the range of 50–75 nM of glucagon. As shown in Fig. 1 in the untreated diabetic animals,
**TABLE IV**

*Influence of Diabetes on Degradation of $^{125}$I-Glucagon by Liver Membranes*

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Control rats (n = 12)</th>
<th>Untreated (n = 10)</th>
<th>Insulin treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>%</td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>TCA precipitation</td>
<td>32.5±4.2</td>
<td>30.8±4.1</td>
<td>34.0±5.0</td>
</tr>
<tr>
<td>Binding to liver membranes</td>
<td>40.6±5.0</td>
<td>40.2±3.0</td>
<td>39.4±3.5</td>
</tr>
<tr>
<td>Adenylate cyclase activation</td>
<td>44.2±4.1</td>
<td>41.6±2.9</td>
<td>45.2±5.1</td>
</tr>
</tbody>
</table>

* Labeled glucagon was exposed to liver membranes (0.2 mg/ml) as described in Methods. The degradation of labeled hormone was determined in the supernates isolated by centrifugation by analyzing three parameters: (a) precipitation by TCA; (b) specific binding to liver membranes; and (c) adenylate cyclase activation of liver membranes. Tubes incubated under identical conditions without membranes served as controls. Percent degradation is calculated as described in Methods. Each value represents the mean±SE.

$^{125}$I-glucagon binding was higher than in control rats at each glucagon concentration. Furthermore, in these animals the amount of glucagon bound at saturation was significantly higher (8.2±0.7 pmol/mg protein) than in control rats (4.2±0.3 pmol/mg protein; P < 0.001). In the high-dose insulin-treated diabetic group (Fig. 1) at saturation, glucagon binding (3.9±0.3 pmol) was virtually the same as in the controls, and in the low-dose insulin treatment group glucagon binding at saturation (5.7±0.4 pmol) was 30% lower than in the untreated diabetic group (P < 0.05), but was still significantly higher than in control animals (P < 0.05; Fig. 1). The range of concentrations over which labeled glucagon showed an increase in binding was similar to that found for activation of adenylate cyclase in all four groups of animals (Fig. 1). The concentration of glucagon giving half-maximal binding or activation of adenylate cyclase was between 3 and 4 nM in all four groups of rats.

**Degradation of glucagon by liver membranes.** To examine the possibility that decreased glucagon degradation by liver membranes from diabetic rats may account for increased glucagon binding by these membranes, the glucagon degradation activity was studied. Table IV shows the degradation of $^{125}$I-glucagon by liver membranes from control and diabetic rats. Glucagon degradation activity was found to be linear over a membrane protein concentration of 0.05–2.5 mg/ml of incubation medium. Liver membranes from control and from untreated and insulin-treated diabetic rats inactivated glucagon to the same extent at a membrane protein concentration of 0.2 mg/ml.

**Effects of diabetes on insulin binding.** As expected (24), the specific binding of $^{125}$I-insulin in the untreated diabetic animals was 40% higher than in control rats (P < 0.01; Table V). In the low-dose insulin-treated diabetic animals, insulin binding was not significantly different from that of control rats, whereas in the high-dose insulin treatment group insulin binding was 30% lower than in control rats (P < 0.05). Analysis of the insulin binding data by Scatchard analysis (18) and average affinity profile (19; Table V) revealed that these differences in insulin binding between different animal groups were mainly a result of a change in the insulin binding capacity rather than to a change in binding affinity.

**TABLE V**

*Influence of Diabetes on Insulin Binding to Liver Membranes*

<table>
<thead>
<tr>
<th>Diabetic rats</th>
<th>Insulin treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Control rats (n = 16)</td>
</tr>
<tr>
<td>Specific binding of $^{125}$I-insulin, %†</td>
<td>23.2±2.1</td>
</tr>
<tr>
<td>Insulin binding capacity, pmol/mg protein‡</td>
<td>1.82±0.16</td>
</tr>
<tr>
<td>Insulin binding affinity (Ke), nM$^{-1}$**</td>
<td>0.82±0.06</td>
</tr>
</tbody>
</table>

* Data are presented as mean±SE.
† Expressed per 0.2 mg membrane protein/ml of incubation medium.
‡ Significantly different from control value, P < 0.01.
§ Significantly different from control value, P < 0.05.
¶ Represents total insulin binding capacity. Calculated by Scatchard analysis (18) and represents the point of intersection of the Scatchard curve on the horizontal axis.
** Represents "empty sites" or highest affinity. Calculated from the “average affinity profile” method of De Meyts and Roth (19).
DISCUSSION

The role of glucagon in fuel homeostasis in normal and diabetic man has received increasing attention in recent years (26, 27). Although the essentiality of glucagon in the pathogenesis of diabetes has been questioned (28), hypersensitivity to the hyperglycemic action of glucagon has been clearly demonstrated in insulin-deprived diabetes (2, 3). Thus, the glycemic response to hyperglucagonemia was 5–15 times greater in insulin-withdrawn diabetics than in normal subjects (2). More recent studies comparing pancreatectomized man and juvenile-onset diabetics indicate that endogenous hyperglucagonemia worsens the hyperglycemia and ketonemia that accompany insulin deficiency (3).

Augmented sensitivity to the hyperglycemic effects of glucagon has also been reported in uremics (29). In a previous study, increased glucagon binding to liver membranes was demonstrated as the cellular mechanism of glucagon hypersensitivity in uremia (6). The current data suggest that a similar mechanism is operative in insulin-deficient diabetics.

In the present study, the untreated diabetic animals exhibited hyperglycemia, weight loss, hypoinsulinemia, and hyperglucagonemia. High-dose insulin treatment of these animals resulted in normoglycemia, normal weight gain, mild hyperinsulinemia, and return of glucagon levels toward base line. The low-dose insulin-treated group demonstrated changes in each of these parameters which were intermediate between the untreated diabetics and the high-dose insulin-treated diabetic animals.

The findings with regard to recovery of plasma membrane protein and marker enzyme activities indicate that there were no significant differences in the membrane purification procedure in the four groups of animals that comprise the present study. As compared to the homogenate, the partially purified plasma membranes from all four groups of rats were enriched 18–20 times in the membrane marker enzyme, 5'-nucleotidase. As indicated by the relative activities of the microsomal enzyme glucose-6-phosphatase in the homogenate and membrane fractions, there was minimal contamination of membranes in each of the experimental groups (Table II). These findings thus indicate that changes in glucagon binding observed in the diabetic rats cannot be ascribed to a systematic effect of the diabetic state on the membrane purification procedure. As previously reported (23, 24), plasma membranes from the untreated diabetic rats had significantly decreased 5'-nucleotidase activity, whereas glucose-6-phosphatase activity was somewhat increased in diabetic rats. Of interest is our observation that insulin treatment resulted in normalization of 5'-nucleotidase activity in diabetic membranes, suggesting that insulin is an important regulator of this membrane enzyme.

The specific binding of 125I-glucagon was approximately twofold higher in the untreated diabetic rats as compared to the control rats (Table III). Insulin treatment of diabetic rats resulted in normalization of glucagon binding in a dose-dependent manner. As shown in Fig. 1, membranes from untreated diabetic rats demonstrated a consistent increase in glucagon binding at all concentrations of glucagon. Furthermore, half-maximal binding was achieved at about the same glucagon concentration in all four groups (Fig. 1). These data suggest that increased glucagon binding in the untreated diabetic rats and in the low-dose insulin-treated diabetic rats is a result of an increase in the number of binding sites rather than a consequence of a change in binding affinity. It should be noted that Davidson and Kaplan (24) in their study of insulin binding in streptozotocin-treated diabetic rats reported that glucagon binding in diabetic animals was not significantly different from that of controls. However, the technique employed by those authors involved the repeated assay of a single pool of membranes obtained from each of two groups (normal and diabetic) rather than separate assays of membranes from each of 16–18 rats in the diabetic and control groups (Table III).

The finding of increased glucagon binding in diabetic animals led us to investigate the adenylate cyclase activity in these animals. We found that the basal adenylate cyclase activity in the untreated diabetic animals was about twofold higher than in control rats and that insulin treatment led to normalization of basal cyclase in a dose-dependent manner (Table III). Of even greater interest are our findings related to the effect of glucagon on adenylate cyclase activity. Glucagon-stimulated adenylate cyclase activity was significantly higher in the untreated diabetic animals as compared with controls. A similar augmentation in epinephrine-stimulated adenylate cyclase activity was observed in the diabetic animals and is in keeping with the increased sensitivity to the hyperkетонemic and hyperglycemic effects of epinephrine in insulin-deprived diabetics (30). Insulin treatment of diabetic animals resulted in reversal of the increased glucagon-stimulated and epinephrine-stimulated adenylate cyclase activity in a manner similar to the changes observed in glucagon binding and in basal adenylate cyclase activity. In contrast to the glucagon-stimulated and epinephrine-stimulated adenylate cyclase activity, sodium fluoride-stimulated adenylate cyclase activity was similar in all four groups of animals. These findings indicate that the augmented response to glucagon and epinephrine in diabetic animals is not a consequence of a nonspecific increase in responsiveness of this system to all stimuli. The close correlation between changes in
glucagon binding (Fig. 1 A) and glucagon-stimulated adenylate cyclase activity (Fig. 1 B) observed in the present study is of particular interest because alterations in hormone binding and in hormone action are not always parallel (31).

Our observations regarding adenylate cyclase activity are supported by the studies of Hepp (32) in mouse liver. In that study basal and glucagon-stimulated adenylate cyclase activity were found to be significantly higher in livers from streptozotocin-treated mice and, in a small number of animals studied, insulin treatment led to the reversal of the glucagon effect toward control values. However, our observations regarding basal and glucagon-stimulated adenylate cyclase activity are at variance with the report of Pilks et al. (33). Those workers observed that basal and maximal glucagon-stimulated adenylate cyclase activity were no different in streptozotocin diabetic rats and control rats. One major difference between our studies and that of Pilks et al. (33) that may possibly account for the different results is the fact that Pilks et al. appear to have used fully purified liver membranes in their experiments, whereas all our studies were done with partially purified plasma membranes. The studies of Pohl et al. (8) clearly indicate that a significant amount of adenylate cyclase activity is lost during the final purification step of preparing plasma membranes. The lower protein yield and lower basal adenylate cyclase activity in the studies of Pilks et al. (33) as compared to the present report support this notion. Furthermore, the degree of diabetes in their animals (blood sugar ≈ 300 mg/100 ml) appears to be milder as compared with the diabetic animals used in the present study.

To examine the possibility that increased glucagon binding and adenylate cyclase activity in diabetic membranes may be a consequence of a significant decrease in glucagon degradation activity in these membranes, we studied the glucagon degradation process in membranes from all groups of animals. As is evident from data in Table IV, the glucagon degrading activity as measured by three different parameters was identical in all four groups. Thus, the observed changes in glucagon binding and adenylate cyclase activity in different groups do not appear to be related to alterations in the glucagon degradation process by these membranes.

The mechanism(s) of increased glucagon binding and augmented adenylate cyclase activity in diabetic animals remains to be established. Both decreased and increased binding of glucagon have been reported in association with hyperglucagonemia. Thus, in starvation (34) and in association with continuous administration of exogenous glucagon, a decrease in glucagon binding is observed. In contrast, the hyperglucagonemia of uremia is associated with increased glucagon binding (6). The finding in the present study that in diabetic rats insulin treatment results in the reversal of increased glucagon binding and of increased basal and glucagon-stimulated adenylate cyclase activity raises the possibility that insulin either directly or through its effect on the plasma glucagon concentration regulates the glucagon receptor. In this regard the studies indicating estrogen stimulation of prolactin receptors (35) and induction of luteinizing hormone receptors in the granulosa cells of the ovary by follicle-stimulating hormone (36) are of great interest. Regardless of the mechanism involved, increased glucagon binding, coupled with augmented basal and glucagon-stimulated adenylate cyclase activity in insulin-deprived diabetic rats, may provide a cellular basis for the increased glycemic and ketonemic response to glucagon in insulin-deprived diabetics (2, 3).

In addition to the changes in glucagon binding and adenylate cyclase activity, our findings demonstrated an increase in insulin binding by liver membranes from diabetic rats which was normalized by low-dose insulin treatment despite the fact that mild hyperglycemia persisted. These observations confirm previous work by Davidson and Kaplan (24). In addition, in the high-dose insulin-treated group, peripheral hyperinsulinemia was achieved (Table I) and insulin binding fell by 30% below normal control levels (Table V). The current data thus provide further confirmation for the conclusion that insulin binding is inversely related to the ambient insulin concentration and that this hormone may modulate its own receptor (37).

ACKNOWLEDGMENTS

We wish to thank Dr. Rosa Hendler for her help and advice and Dr. Mary A. Boot of The Lilly Research Laboratories, Indianapolis, Ind., for kindly supplying crystalline glucagon and insulin. We also wish to thank Mrs. Hana Cohen for her excellent technical help and Ms. Deborah Drauszewski and Mrs. Barbara Hoxsie for their secretarial assistance.

This work was supported by National Institutes of Health research grant AM-13526.

REFERENCES